The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Molecularly Imprinted Polymer Nanoparticles: An Emerging Versatile Platform for Cancer Therapy
Open accessAbstract
Molecularly imprinted polymers (MIPs) are chemically synthesized affinity materials with tailor‐made binding cavities complementary to the template molecules in shape, size, and functionality. Recently, engineering MIP‐based nanomedicines to improve cancer therapy has become a rapidly growing field and future research direction. Because of the unique properties and functions of MIPs, MIP‐based nanoparticles (nanoMIPs) are not only alternatives to current nanomaterials for cancer therapy, but also hold the potential to fill gaps associated with biological ligand‐based nanomedicines, such as immunogenicity, stability, applicability, and economic viability. Here, we survey recent advances in the design and fabrication of nanoMIPs for cancer therapy and highlight their distinct features. In addition, how to use these features to achieve desired performance, including extended circulation, active targeting, controlled drug release and anti‐tumor efficacy, is discussed and summarized. We expect that this minireview will inspire more advanced studies in MIP‐based nanomedicines for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Maeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179
Sialic acids sweeten a tumor's life
Büll, C., Stoel, M. A., den Brok, M. H., & Adema, G. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0728 · Cited by 496
Recent Advances in Cell Membrane–Camouflaged Nanoparticles for Cancer Phototherapy
Zhen, X., Cheng, P., & Pu, K. (2019) · Small · doi:10.1002/smll.201804105 · Cited by 483
Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Zhao, N., Qin, Y., Liu, H., & Cheng, Z. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520617666170419143459 · Cited by 86
Cited by
Antibacterial Nanomaterials: Mechanisms, Impacts on Antimicrobial Resistance and Design Principles
Xie, M., Gao, M., Yun, Y., Malmsten, M., Rotello, V. M., Zboril, R., Akhavan, O., Kraskouski, A., Amalraj, J., Cai, X., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202217345 · Cited by 491
Cancer nanotechnology: current status and perspectives
Kemp, J. A., & Kwon, Y. J. (2021) · Nano Convergence · doi:10.1186/s40580-021-00282-7 · Cited by 266
Zhang, H., Mu, Y., Han, C., & Zhou, Y. (2025) · Small · doi:10.1002/smll.202412303 · Cited by 14
Metadata
- Authors
- Xu, S., Wang, L., & Liu, Z.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2020-11-23
- Volume
- 60
- Issue
- 8
- Pages
- 3858-3869
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W3048580781
- Cited by
- 230
- References
- 7
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.